A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Completed · Phase 1
Conditions studied: Prostatic Neoplasms
In brief
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Key facts
- Study ID
- NCT05022849
- Run by
- Janssen Research & Development, LLC
- People needed
- 15
- Starts
- 2021-09-28
- Expected to finish
- 2026-03-11
- Last updated by the study team
- 2026-04-17
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Histology: Metastatic CRPC (mCRPC) with histologic confirmation of adenocarcinoma. Metastatic CRPC with neuroendocrine features or mixed histology is excluded
- Prior Therapy: Prior treatment with at least 1 prior novel androgen receptor AR-targeted therapy (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), or at least 1 prior chemotherapy (example, docetaxel)
- Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or detectable prostate-specific antigen (PSA) levels based on local laboratory results
- Fertile participants must use a condom with spermicide during any sexual contact with a woman of childbearing potential, including pregnant women, from the time of signing the ICF until 1 year after receiving a JNJ-75229414 infusion. Vasectomized participants must agree to use a condom to protect any sexual partner from exposure to semen for 1 year after receiving the last dose of study drug. Contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies
You may not qualify if…
- Prior Grade 4 Cytokine release syndrome (CRS) or Grade 3 or Grade 4 neurotoxicity related to any T cell redirection (Bispecific cluster of differentiation [CD 3])
- Prior Kallikrein 2 (KLK2)-targeted therapy
- Prior chimeric antigen receptor T cell (CAR-T) therapy
- Receiving systemic treatment less than or equal to (<=) 6 months prior to signing informed consent) for any invasive malignancy other than prostate cancer unless approved by the sponsor. Bisphosphonates initiated greater than or equal to (>=) 6 weeks prior signing informed consent are allowed
- Less than 2 weeks between last administration anti-androgen agents (example, abiraterone or enzalutamide), poly adenosine diphosphate-ribose polymerase (PARP) inhibitors (example, olaparib) or radiotherapy, and less than 3 weeks between last administration of cytotoxic chemotherapy (example, docetaxel), radionuclides (example, radium-223, lutetium-177-Prostate-specific membrane antigen [PSMA]-617) or an investigational agent, and apheresis
Where it is running
- City of Hope Cancer Center — Duarte, California, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- University Of Minnesota — Minneapolis, Minnesota, United States
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
- Columbia University Medical Center — New York, New York, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- University of Utah Huntsman Cancer Institute — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.